Last reviewed · How we verify
ATGC-100 100U
ATGC-100 is an antithrombin-based therapeutic that enhances natural anticoagulation pathways.
ATGC-100 is an antithrombin-based therapeutic that enhances natural anticoagulation pathways. Used for Thrombotic disorders or thromboembolism prevention (specific indication in Phase 3 not publicly detailed).
At a glance
| Generic name | ATGC-100 100U |
|---|---|
| Sponsor | EuBiologics Co.,Ltd |
| Drug class | Anticoagulant (antithrombin-based) |
| Target | Thrombin and coagulation factors (Factor Xa, IIa, and others) |
| Modality | Biologic |
| Therapeutic area | Cardiovascular / Hematology |
| Phase | Phase 3 |
Mechanism of action
ATGC-100 appears to be a recombinant or modified antithrombin product designed to potentiate endogenous anticoagulation mechanisms. Antithrombin is a natural inhibitor of thrombin and other coagulation factors, and this formulation may be engineered for improved stability, bioavailability, or therapeutic efficacy in thrombotic conditions.
Approved indications
- Thrombotic disorders or thromboembolism prevention (specific indication in Phase 3 not publicly detailed)
Common side effects
- Bleeding
- Injection site reactions
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |